Redeye returns with an update following Annexin’s Q3 report.
iZafe vinner en upphandling med Västra Götalandsregionen för tillhandahållande av omkring 2000 Dosel...
ChromoGenics just announced that during Q3 2023 it had an aggregated order intake of SEK8.
OrderYOYO announced on Wednesday, October 18th, the company’s performance during Q3-23 and shows a c...
Huddlestock announced on Tuesday, October the 17th, that Norse Securities AS (“Norse”) has selected ...
Redeye shares its preview of BONESUPPORT’s Q3 2023e results, due October 26.
-11% organisk tillväxt… Efterfrågan i Supply Chain Solutions försvagades i alla större kundsegment o...
RanLOS AB (publ) (”RanLOS” eller ”Bolaget”) utvecklar och säljer en nyckelfärdig lösning inom testni...
Intäkterna minskade men rörelseresultatet ökade under kvartalet.
Redeye provides a brief initial take on Ultimovacs reporting more granular NIPU data.
Redeye thinks Jondetech continues taking rather significant steps towards a commercial phase - but a...
CMD in Stockholm focused on mesdopetam Potential Ph 3 programme outlined by KOL End-of-phase 2 meeti...
Redeye comments on Freemelt ahead of its Q3 results (due 8 Nov).
Redeye provides an update on Fantasma Games ahead of its Q3 results (due 8 Nov).
Markedly softer demand, but margins are improving We lower adj.
Adj. EBITA SEK 211m (-13% vs. ABGSCe 241m) Consensus EBITA likely to come down by 5-7% 10x 2023e EBI...
Today, Nanologica announced that it has successfully fulfilled an order placed last year for the eva...
Redeye is shocked to learn that one of Alelion's largest customers is refusing to fulfil its part of...
Q3e sales SEK 234m, +5% y-o-y (-7% org.), adj. EBITA margin 7.
Redeye comments on Invisio ahead of its Q3-results (due 25 October) where we expect continued strong...
